People
Actor, director and advocate Rob Reiner opened the third day of the 2018 BIO International Convention.
Unity Biotechnology has raised $222 million in venture capital, raised $85 million in an initial public offering (IPO) in May, and has a value of $700 million. All without having a product to sell.
Appaloosa Management’s David Tepper and Senator Investment Group’s Douglas Silverman sent a letter to Allergan’s board of directors yesterday asking—or demanding—that the company split the roles of chief executive officer and chairman.
South San Francisco-based Senti Biosciences is getting a new Chief Financial Officer and Chief Business Officer. Former Sangamo Therapeutics Senior Vice President and Chief Business Officer Curt Herberts will join Senti later this month.
Robin Roberts, ABC’s Good Morning America journalist and anchor, kicked off the 2018 BIO International Convention in Boston with her keynote address.
Portola Pharmaceuticals’ chief executive officer, William Lis, plans to retire as both chief executive and board member.
There have been a number of leadership changes in the life sciences industries over the past week. BioSpace compiled a roundup of the changing landscape of the c-suite and boards of directors across the industry.
It has been one year since Mitsubishi Tanabe Pharma America’s Radicava was approved as the first treatment for amyotrophic lateral sclerosis (ALS) in more than 20 years. Since its approval, MTPA has been aggressive in its efforts to get the medication in the hands of ALS patients.
Roseanne Barr has courted controversy with comments concerning immigration, the Parkland school shooting, and various racist and anti-Semitic conspiracy theories. She later blamed these comments on her use of the sleep medication Ambien.
Shares of Arcturus Therapeutics are up nearly 10 percent this morning after the company announced it reached a settlement with its former chief executive officer and replaced four members of its board of directors with four new ones.
PRESS RELEASES